Genprex Reports $3.8 Million Net Loss in Q3 2025, Down 12% Year-Over-Year

Genprex, Inc. reported its financial results for the third quarter of 2025, revealing a net loss of $3.8 million, a decrease of 12% from the $4.3 million loss recorded in the same period of 2024. For the nine months ending September 30, 2025, the company reported a net loss of $12.4 million, down 26% from $16.8 million in the prior year. The reduction in losses is attributed to the closure of the Acclaim-2 clinical trial, which led to decreased clinical and manufacturing expenses, as well as cost-cutting measures that reduced overall staffing from 19 employees to 13.

Total operating expenses for the third quarter of 2025 were approximately $3.3 million, down from $4.3 million in the same quarter of 2024. Research and development expenses decreased by 20% to $2.2 million, primarily due to changes in clinical trial enrollment and a reduction in R&D staff. General and administrative expenses also saw a significant decline, dropping 26% to $1.2 million, reflecting the company's efforts to implement expense reduction strategies.

As of September 30, 2025, Genprex's cash and cash equivalents stood at $1.1 million, down from $1.6 million at the end of 2024. The company has been actively raising capital, generating approximately $10.7 million from financing activities in the first nine months of 2025, compared to $8 million in the same period of 2024. This included proceeds from an equity line of credit with Lincoln Park Capital Fund, which allows for the sale of up to $12.5 million in common stock over a 24-month period.

Strategically, Genprex has made significant advancements in its clinical trials, particularly with its lead oncology drug candidate, REQORSA, which is currently in the Phase 2a expansion of the Acclaim-1 trial. The company has received FDA Fast Track Designation for this treatment in patients with non-small cell lung cancer who have progressed on prior therapies. Additionally, Genprex has formed a wholly-owned subsidiary, Convergen Biotech, to focus on its diabetes gene therapy program, which is in preclinical development.

Looking ahead, Genprex anticipates that its current cash reserves will fund operations and clinical trial activities into March 2026. However, the company acknowledges the need for additional capital to support ongoing and future clinical trials, including those for its diabetes program. The management has expressed uncertainty regarding its ability to maintain liquidity and continue as a going concern, emphasizing the importance of securing further funding to sustain its operations and development efforts.